Search | Clinical Trials Finder

Conditions: Delayed Onset Muscle Soreness, DOMS
Interventions: SST-0225, Placebo; Drug
Lead sponsor: Strategic Science & Technologies, LLC; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 156 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Hollywood, Florida • South Miami, Florida • Springfield, Missouri

Conditions: Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Skin Neoplasms, Skin Diseases, Neoplasms, Basal Cell, Neoplasms, Squamous Cell, Carcinoma
Interventions: 5-fluorouracil, Placebo, vehicle control; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 954 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 13
States / cities: Palo Alto, California • San Diego, California • Denver, Colorado + 10 more

Conditions: Acne Vulgaris
Interventions: Tazarotene Cream 0.1%, Tazorac®, Placebo; Drug
Lead sponsor: Fougera Pharmaceuticals Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 25
States / cities: Tucson, Arizona • Conway, Arkansas • Hot Springs, Arkansas + 20 more

Conditions: Acne Vulgaris
Interventions: Trifarotene cream, Doxycycline hyclate, Trifarotene Vehicle, Doxycycline Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 25
States / cities: Fort Smith, Arkansas • Hot Springs, Arkansas • Rogers, Arkansas + 21 more

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 64
States / cities: Birmingham, Alabama • Hoover, Alabama • Gilbert, Arizona + 49 more

Conditions: Atopic Dermatitis
Interventions: PF-06700841, Vehicle (Placebo); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 36
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Encinitas, California + 28 more

Conditions: Vitiligo
Interventions: ARQ-252 cream 0.3%, ARQ-252 Vehicle cream, NB-UVB phototherapy active treatment, NB-UVB phototherapy sham treatment; Drug · Device
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 5
States / cities: San Diego, California • Coral Gables, Florida • Rolling Meadows, Illinois + 2 more

Conditions: Acne Vulgaris
Interventions: UHE-101 Cream, Vehicle Cream; Drug · Other
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Diego, California

Conditions: Pruritus, Atopic Dermatitis
Interventions: difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 61
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more

Conditions: Rosacea
Interventions: Oxymetazoline Hydrochloride, Rhofade Cream, 1%, Placebo; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Lynchburg, Virginia

Conditions: BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include, Vaginal Discharge Color, Odor, and Consistency, Vulvovaginal Itching and Irritation (Subjective) Absent, Mild, Moderate, or Severe, Vulvovaginal Inflammation (Objective) Absent, Mild, Moderate, or Severe
Interventions: clindamycin phosphate vaginal cream 2%, placebo; Drug · Other
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 15
States / cities: Birmingham, Alabama • La Mesa, California • San Diego, California + 12 more

Conditions: Vulvar and Vaginal Atrophy
Interventions: Estrace® Cream, Estradiol Vaginal Cream, Vehicle Cream; Drug
Lead sponsor: Prasco LLC; Industry
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 27
States / cities: Sacramento, California • San Diego, California • Denver, Colorado + 23 more

Conditions: Sprain, Strain, Acute Soft Tissue Injury
Interventions: Topical Ketoprofen 10% Cream, Topical Placebo Cream; Drug
Lead sponsor: Imprimis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Stretch Marks, Striae Distensae, Cosmetic Appearance of Stretch Marks
Interventions: Placebo Vehicle Cream, Centella Asiatica Cream; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Vitiligo
Interventions: Ruxolitinib cream, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 6
States / cities: Fountain Valley, California • Irvine, California • Washington D.C., District of Columbia + 3 more

Conditions: Head Lice
Interventions: Ivermectin cream, vehicle control; Drug
Lead sponsor: Topaz Pharmaceuticals Inc; Industry
Eligibility: 2 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 12
States / cities: Yuma, Arizona • Los Angeles, California • Delray Beach, Florida + 9 more

Conditions: Acne Vulgaris
Interventions: Tretinoin cream 0.1%, RETIN-A® Cream, Vehicle of the test product; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 455 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Rosacea
Interventions: Brimonidine 0.33% gel (Br), CD07805/47 (Br) placebo gel, Ivermectin 1% cream (IVM), CD5024 (IVM) placebo cream; Drug · Other
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 7
States / cities: Fort Smith, Arkansas • Rogers, Arkansas • Sacramento, California + 4 more

Conditions: Lentigo
Interventions: lidocaine 2.5%/prilocaine 2.5% topical anesthetic, lidocaine 7%/tetracaine 7% topical anesthetic, placebo vehicle, Q-switched 532nm Laser; Drug · Device
Lead sponsor: Northwestern University; Other
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Actinic Keratosis (AK)
Interventions: Low dose DFD07 once daily, High dose DFD07 once daily, High dose DFD07 twice daily, Placebo twice daily; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 20
States / cities: Cerritos, California • Fremont, California • Palm Springs, California + 14 more

Conditions: Dermatitis, Atopic
Interventions: Pimecrolimus plus topical corticosteroid (TCS), Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS); Drug
Lead sponsor: Novartis; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 13
States / cities: Huntington Beach, California • San Diego, California • Denver, Colorado + 10 more

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 200 participants
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Novartis Pharmaceuticals, New Jersey

Conditions: Frontal Fibrosing Alopecia
Interventions: Delgocitinib cream, Delgocitinib cream vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Bioequivalence
Interventions: Oxymetazoline hydrochloride Cream, 1%, Rhofade™ (oxymetazoline) cream, 1%, Placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS)

CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial

A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris

A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"

Study to Evaluate the Equivalence of Estradiol Vaginal Cream to Reference Standard in the Treatment of Vaginal Atrophy

Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury

Topical Centella Asiatica and the Cosmetic Appearance of Stretch Marks

A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)

Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects

To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris

MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.

The Effect of Topical Anesthetics on Patients' Pain and Operative Experience During Treatment With QSwitched Laser

A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period

Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis

Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

A Study Comparing Oxymetazoline 1% Cream to RHOFADE